More than 10% of people in clinical trials had one or more of urinary tract infections, vaginal infections, upper abdominal pain, or diarrhea.
Tafamidis
Clofibride
Tirofiban
Etofibrate
Epitiostanol
Bosentan
Oprelvekin
Sitaxentan